AMLX
NASDAQAmylyx Pharmaceuticals Inc.
Website
News25/Ratings12
Price$17.30+0.78 (+4.69%)
2026-01-202026-04-23
News · 26 weeks57-86%
2025-10-262026-04-19
Mix3690d
- Insider15(42%)
- SEC Filings11(31%)
- Other7(19%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Amylyx Pharmaceuticals Inc.DEFA14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECSEC Form DEF 14A filed by Amylyx Pharmaceuticals Inc.DEF 14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on Wednesday, April 15, 2026, at 8:45 a.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.SCHEDULE 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- SECAmylyx Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric HypoglycemiaLast participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants Topline data readout on track; anticipated in Q3 2026 LUCIDITY is evaluating the FDA-agreed-upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the last participant has been randomized and dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with U.S. Food and Drug Administration (FDA) Breakthrough Therapy De
- INSIDERChief Financial Officer Frates James M was granted 95,990 shares, increasing direct ownership by 58% to 261,628 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina was granted 74,660 shares, increasing direct ownership by 56% to 209,090 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Cohen Joshua B was granted 248,865 shares, increasing direct ownership by 7% to 3,583,548 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Klee Justin B. was granted 248,865 shares, increasing direct ownership by 7% to 3,583,481 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Medical Officer Bedrosian Camille L was granted 95,990 shares, increasing direct ownership by 57% to 265,285 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Klee Justin B. sold $423,760 worth of shares (29,282 units at $14.47), decreasing direct ownership by 0.87% to 3,334,616 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Cohen Joshua B sold $424,120 worth of shares (29,282 units at $14.48), decreasing direct ownership by 0.87% to 3,334,683 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Financial Officer Frates James M sold $114,851 worth of shares (7,909 units at $14.52), decreasing direct ownership by 5% to 165,638 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Medical Officer Bedrosian Camille L sold $94,205 worth of shares (6,461 units at $14.58), decreasing direct ownership by 4% to 169,295 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina sold $99,378 worth of shares (6,844 units at $14.52), decreasing direct ownership by 5% to 134,430 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- SECSEC Form S-8 filed by Amylyx Pharmaceuticals Inc.S-8 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- ANALYSTStifel initiated coverage on Amylyx Pharmaceuticals with a new price targetStifel initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $21.00
- SECSEC Form S-3ASR filed by Amylyx Pharmaceuticals Inc.S-3ASR - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECSEC Form 10-K filed by Amylyx Pharmaceuticals Inc.10-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECAmylyx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsRecruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as
- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- PRAmylyx Pharmaceuticals to Participate in Upcoming March Investor ConferencesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person: TD Cowen 46th Annual Health Care Conference: Fireside Chat on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, Massachusetts Leerink Global Healthcare Conference: Fireside chat on Tuesday, March 10, 2026, at 8:00 a.m. ET in Miami, Florida A live webcast of both presentations can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following t